AU2019332400B2 - Method for producing fibroblast, and G-CSF-positive fibroblast mass - Google Patents

Method for producing fibroblast, and G-CSF-positive fibroblast mass Download PDF

Info

Publication number
AU2019332400B2
AU2019332400B2 AU2019332400A AU2019332400A AU2019332400B2 AU 2019332400 B2 AU2019332400 B2 AU 2019332400B2 AU 2019332400 A AU2019332400 A AU 2019332400A AU 2019332400 A AU2019332400 A AU 2019332400A AU 2019332400 B2 AU2019332400 B2 AU 2019332400B2
Authority
AU
Australia
Prior art keywords
fibroblasts
positive
hcf
csf
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019332400A
Other languages
English (en)
Other versions
AU2019332400A1 (en
Inventor
Takahiro IWAMIYA
Tomoyuki OSUGI
Masaya Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lymphogenix Ltd
Original Assignee
Lymphogenix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lymphogenix Ltd filed Critical Lymphogenix Ltd
Publication of AU2019332400A1 publication Critical patent/AU2019332400A1/en
Assigned to LYMPHOGENIX LIMITED reassignment LYMPHOGENIX LIMITED Request for Assignment Assignors: METCELA INC.
Application granted granted Critical
Publication of AU2019332400B2 publication Critical patent/AU2019332400B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Vascular Medicine (AREA)
AU2019332400A 2018-08-29 2019-08-29 Method for producing fibroblast, and G-CSF-positive fibroblast mass Active AU2019332400B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-160898 2018-08-29
JP2018160898 2018-08-29
PCT/JP2019/033835 WO2020045547A1 (ja) 2018-08-29 2019-08-29 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団

Publications (2)

Publication Number Publication Date
AU2019332400A1 AU2019332400A1 (en) 2021-04-01
AU2019332400B2 true AU2019332400B2 (en) 2025-06-26

Family

ID=69642802

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019332400A Active AU2019332400B2 (en) 2018-08-29 2019-08-29 Method for producing fibroblast, and G-CSF-positive fibroblast mass

Country Status (10)

Country Link
US (1) US20210254009A1 (https=)
EP (1) EP3845635A4 (https=)
JP (2) JP6883904B2 (https=)
KR (1) KR102883773B1 (https=)
CN (1) CN112639082A (https=)
AU (1) AU2019332400B2 (https=)
CA (1) CA3110831A1 (https=)
IL (1) IL281081B (https=)
SG (1) SG11202102028SA (https=)
WO (1) WO2020045547A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3845635A4 (en) * 2018-08-29 2022-06-15 Metcela Inc. PROCEDURE FOR PREPARING FIBROBLAST AND G-CSF-POSITIVE FIBROBLAST MASS
WO2021177387A1 (ja) * 2020-03-04 2021-09-10 株式会社メトセラ エリスロポエチン産生能が亢進された線維芽細胞
CA3211113A1 (en) 2021-03-04 2022-09-09 Metcela Inc. Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same
US20240316113A1 (en) 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease
CN119685401A (zh) * 2024-06-03 2025-03-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种改造成纤维细胞的方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3168297A1 (en) * 2014-07-11 2017-05-17 Metcela Inc. Cardiac cell culture material

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1886150B (zh) * 2003-10-27 2010-05-26 学校法人庆应义塾 含有g-csf的成纤维细胞动员剂及创伤治疗剂
US9987310B2 (en) * 2013-11-27 2018-06-05 University Of Louisville Research Foundation, Inc. Cardiac progenitor cells and methods of use therefor
CN107881145A (zh) * 2016-09-26 2018-04-06 新乡医学院 一种分选大鼠心成纤维细胞cd90+亚群的方法及其应用
KR102407387B1 (ko) * 2017-02-24 2022-06-10 가부시키가이샤 메토세라 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법
EP3845635A4 (en) * 2018-08-29 2022-06-15 Metcela Inc. PROCEDURE FOR PREPARING FIBROBLAST AND G-CSF-POSITIVE FIBROBLAST MASS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3168297A1 (en) * 2014-07-11 2017-05-17 Metcela Inc. Cardiac cell culture material

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H PHILLIP KOEFFLER ET AL: "Recombinant Human TNFa Stimulates Production of Granulocyte Colony-Stimulating Factor", BLOOD, vol. 70, no. 1, 1 July 1987 (1987-07-01), pages 55 - 59, XP055696815 *
YOSHIFUKU KOUSUKE ET AL: "IL-4 and TNF-[alpha] increased the secretion of eotaxin from cultured fibroblasts of nasal polyps with eosinophil infiltration", RHINOLOGY, 1 January 2007 (2007-01-01), Utrecht, pages 235 - 241. *
ZHAO JINJUN ET AL: "A protocol for the culture and isolation of murine synovial fibroblasts", BIOMEDICAL REPORTS MAY 2014 SPANDIDOS PUBLICATIONS GBR, vol. 5, no. 2, 1 August 2016 (2016-08-01), Greece, pages 171 - 175. *

Also Published As

Publication number Publication date
EP3845635A4 (en) 2022-06-15
IL281081A (en) 2021-04-29
CA3110831A1 (en) 2020-03-05
IL281081B (en) 2022-07-01
AU2019332400A1 (en) 2021-04-01
SG11202102028SA (en) 2021-03-30
JP2021118728A (ja) 2021-08-12
KR20210049892A (ko) 2021-05-06
EP3845635A1 (en) 2021-07-07
WO2020045547A1 (ja) 2020-03-05
KR102883773B1 (ko) 2025-11-07
JP6883904B2 (ja) 2021-06-09
CN112639082A (zh) 2021-04-09
JP7428389B2 (ja) 2024-02-06
JPWO2020045547A1 (ja) 2021-02-15
US20210254009A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
AU2019332400B2 (en) Method for producing fibroblast, and G-CSF-positive fibroblast mass
AU2018223739B2 (en) Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use
JP2020072725A (ja) 向上された臍帯由来付着型幹細胞、その製造方法及びその用途
TW201809269A (zh) 細胞培養用培養基及細胞培養方法
US20130251691A1 (en) Embryonic Stem Cell-Derived Cardiomyocytes and a Cellular Therapeutic Agent Comprising the Same as an Active Ingredient
CN102712897B (zh) 心脏组织来源细胞
US20220411761A1 (en) Fibroblast having enhanced erythropoietin production ability
JP2023001294A (ja) 臓器線維症の予防または治療剤
US20190224243A1 (en) Enhancement of the Beneficial Effects of Mesenchymal Stem Cell Treatment by the Caveolin-1 Scaffolding Domain Peptide and Subdomains
US20160346330A1 (en) Cardiac, mesenchymal and endothelial progenitor cell (cpc) chimeras and methods for making and using them
RU2800644C2 (ru) Способ получения фибробластов и г-ксф-положительная фибробластная масса
CN117120063A (zh) 淋巴管新生促进因子表达成纤维细胞以及含有该细胞的医药组合物
Nagayasu et al. Reversible and irreversible tumor progression of a weakly malignant rat mammary carcinoma cell line by in vitro exposure to epidermal growth factor.
WO2024176514A1 (ja) 心臓内幹細胞を含む細胞集団
WO2025178117A1 (ja) 破骨細胞への分化抑制に用いるための組成物
ES2666351T3 (es) Composición y método de células madre para la preservación del tejido cardíaco
US20190343888A1 (en) C-kit-positive bone marrow cells and uses thereof
Luo Marrow stromal cells for myocardial regeneration
MD FOR MYOCARDIAL REGENERATION

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LYMPHOGENIX LIMITED

Free format text: FORMER APPLICANT(S): METCELA INC.

FGA Letters patent sealed or granted (standard patent)